Xcovery was represented at the WCLC 2024 in San Diego with new data on ensartinib activity in ALK or MET positive NSCLC and the dose escalation results of MRX-2843 in NSCLC. Giovanni Selvaggi M.D., Xcovery’s CMO attended the conference. Betta pharmaceutical mini oral presentation on ensartinib as MET inhibitor MA06.11 Resolution Bio mini oral on ensartinib in vitro resistance pattern MA06.09 Poster on real world ensartinib long term response predictors P1.12B.04 Poster on Meryx phase I OSI+MRX study P1.12A.09

Yang Xia| Phase II trial of ensartinib for advanced or metastatic non-small-cell lung cancer with MET exon 14 skipping mutations 1 Phase II trial of ensartinib for advanced or metastatic non- small-cell lung cancer with MET exon 14 skipping mutations Yang Xia MD, PhD Department of Pulmonary and Critical Care Medicine, Second Affiliated Hospital Zhejiang University School of Medicine, China Yang Xia| Phase II trial of ensartinib for advanced or metastatic non-small-cell lung cancer with MET exon 14 skipping mutations 2 Introduction • Met proto-oncogene exon 14 skipping (METex14) mutations have been identified as treatable non-small cell lung cancer (NSCLC) tumor driver genes. • Ensartinib is originally considered as a second-generation ALK inhibitor, our pre-clinical and pilot clinical data have exhibited the potential of ensartinib as a MET inhibitor. • T h i s s i n g l e - a r m , m u l t i - c e n t e r , p h a s e I I s t u d y (ChiCTR2100048767) aimed to evaluate the efficacy and safety of ensartinib for advanced or metastatic NSCLC with METex14 mutations 1. Shi Y, et al., Journal of Thoracic Oncology, 2014; 2. Drilon A, et al., Journal of Thoracic Oncology, 2017. Yang Xia| Phase II trial of ensartinib for advanced or metastatic non-small-cell lung cancer with MET exon 14 skipping mutations 3 Study design N=30 ORR DOR, DCR, PFS, Safety • Aged ≥18 years • Advanced or metastatic NSCLC • METex14 mutations • Wild type EGFR/ALK/ROS1 • TKI-naïve • ≥1 measurable lesion • Disease progression or intolerance or abandonment after ≥1 cycle of platinum- based chemotherapy • ECOG PS ≤2 U n t i l d i s e a s e p r o g r e s s i o n , unacceptable toxicity, o r c o n s e n t withdrawal Efficacy analysis set (EAS): Patients who received at least one dose of the drug and could be evaluated for efficacy according to the RECIST v. 1.1 criteria. Safety analysis set (SAS): Patients who received at least one dose of the drug and could be evaluated for safety. Ensartinib 225 mg once daily Biomarkers (ctDNA) Exploratory endpoints Secondly endpoints Primary endpoints Abbreviations: METex14, Met proto-oncogene exon 14 skipping; ECOG PS, Eastern Cooperative Oncology Group Performance Status; ORR, objective response rate; DOR, duration of response; DCR, disease control rate; PFS, progression-free survival; RECIST, Response Evaluation Criteria in Solid Tumors. Key eligibility criteria: Yang Xia | Phase II trial of ensartinib for advanced or metastatic non-small-cell lung cancer with MET exon 14 skipping mutations 4 Overall (n=30) Age, median (range), years 69.4 (47, 84) Sex (n, %) Male 14 (46.7) Female 16 (53.3) Tumor Histology (n, %) Adenocarcinoma 27 (90.0) Squamous cell carcinoma 2 (6.7) Non of specific 1 (3.3) Disease stage at baseline (n, %) Stage III 6 (20.0) Stage IV 24 (80.0) ECOG PS (n, %)   1 20 (66.7) ≥2 10 (33.3) Patient characteristics and efficacy results EAS (n=30) BOR, n (%) PR 16 (53.3) SD 10 (33.3) PD 4 (13.3) ORR, % (95% Cl) 53.3 (35.5-71.2) DCR, % (95% Cl) 86.7 (74.5-98.8) Patient characteristics Abbreviations: BOR, best overall response; PR, partial response; SD, stable disease; PD, progression disease. Tumor response Waterfall-plot of response • The ORR and DCR were 53.3% and 86.7%, respectively. Yang Xia | Phase II trial of ensartinib for advanced or metastatic non-small-cell lung cancer with MET exon 14 skipping mutations 5 Efficacy results Median PFS (months) 6.0 (95% CI, 3.0-8.8) ctDNA status and ORRPFS Time on treatment • Of the 16 patients with objective responses, treatment was still ongoing in 5 patients at the data cutoff. • The median DoR was 7.9 months. • The median PFS was 6.0 months. • CtDNA clearance at week 4 of ensartinib treatment corelated with best ORR (80%), followed by patients who tested negative for ctDNA both before and week 4 of ensartinib (42.9%), while those with ctDNA residual showed the worst response rate (20%). DoR Median DoR (months) 7.9 (95% CI, 4.8-8.7) Yang Xia | Phase II trial of ensartinib for advanced or metastatic non-small-cell lung cancer with MET exon 14 skipping mutations 6 Safety results SAS (n=30) Any grade AEs 24 (80) Rash 14 (46.7) Anemia 7 (23.3) ALT increased 7 (23.3) AST increased 7 (23.3) Pruritus 6 (20) Grade ≥3 AEs 7 (23.3) Rash 4 (13.3) Anemia 1 (3.3) ALT increased 1 (3.3) Bilirubin increased 1 (3.3) AE leading to dose reduction of study treatment 1 (3.3) AE leading to discontinuation of study treatment 1 (3.3) Overall Summary of AEs Most frequent AEs • Adverse events (AEs) were reported in 24 patients (80%), with 7 (23.3%) of grade 3. Yang Xia | Phase II trial of ensartinib for advanced or metastatic non-small-cell lung cancer with MET exon 14 skipping mutations 7 Conclusion • Ensartinib demonstrated encouraging anti-tumor activity in patients with advanced or metastatic NSCLC harboring METex14 in the second line setting. − ORR was 53.3% and DCR was 86.7%. − Median DOR was 7.9 months (95% CI, 4.8-8.7). − Median PFS was 6.0 months (95% CI, 3.0-8.8). • Ensartinib was generally well tolerated with a manageable safety profile. No serious events or treatment-related deaths occurred. • This regimen is expected to provide a new treatment option for this population. Yang Xia | Phase II trial of ensartinib for advanced or metastatic non-small-cell lung cancer with MET exon 14 skipping mutations 8 Acknowledgements We also thank all the investigators and staff at the study centers. Thanks to all the patients and their families.

The release as fetched from its publisher. xcovery.com ↗